{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:52:37Z","timestamp":1791312757957,"version":"4.3.1"},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T00:00:00Z","timestamp":1312848000000},"content-version":"vor","delay-in-days":39,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biotech and App Biochem"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hemophilia B is a genetic disease of the coagulation system that affects one in 30,000 males worldwide. Recombinant human Factor IX (rhFIX) has been used for hemophilia B treatment, but the amount of active protein generated by these systems is inefficient, resulting in a high\u2010cost production of rhFIX. In this study, we developed an alternative for rhFIX production. We used a retrovirus system to obtain two recombinant cell lines. We first tested rhFIX production in the human embryonic kidney 293 cells (293). Next, we tested a hepatic cell line (HepG2) because FIX is primarily expressed in the liver. Our results reveal that intracellular rhFIX expression was more efficient in HepG2\/rhFIX (46%) than in 293\/rhFIX (21%). The activated partial thromboplastin time test showed that HepG2\/rhFIX expressed biologically active rhFIX 1.5 times higher than 293\/rhFIX (<jats:italic>P<\/jats:italic> = 0.016). Recovery of rhFIX from the HepG2 by reversed\u2010phase chromatography was straightforward. We found that rhFIX has a pharmacokinetic profile similar to that of FIX purified from human plasma when tested in hemophilic B model. HepG2\/rhFIX cell line produced the highest levels of rhFIX, representing an efficient <jats:italic>in vitro<\/jats:italic> expression system. This work opens up the possibility of significantly reducing the costs of rhFIX production, with implications for expanding hemophilia B treatment in developing countries.<\/jats:p>","DOI":"10.1002\/bab.32","type":"journal-article","created":{"date-parts":[[2011,8,9]],"date-time":"2011-08-09T18:21:50Z","timestamp":1312914110000},"page":"243-249","source":"Crossref","is-referenced-by-count":15,"title":["Stable and high\u2010level production of recombinant Factor IX in human hepatic cell line"],"prefix":"10.1002","volume":"58","author":[{"given":"Andrielle","family":"de Castilho Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparecida","family":"Fontes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalia","family":"Gonsales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamilla","family":"Swiech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Picanco\u2010Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Faca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Covas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,8,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2006.11.001"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3600"},{"key":"e_1_2_8_4_2","first-page":"4","volume":"35","author":"Harrison S.","year":"1998","journal-title":"Semin. Hematol."},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.1016\/S0021-9258(18)67559-3","volume":"261","author":"Kaufman R. J.","year":"1986","journal-title":"J. Biol. Chem."},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03913.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1006\/mthe.2000.0075"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1055\/s-0037-1613013","volume":"87","author":"Rodriguez M. H.","year":"2002","journal-title":"Thromb. Haemost."},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(93)22029-F"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199305000-00007"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1258"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1293-397"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M505373200"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1997.8.2-125"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01367.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01085.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-008-9051-x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1991.2.1-27"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb07958.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1172\/JCI109073","volume":"61","author":"Di Scipio R. G.","journal-title":"J. Clin. Invest."},{"key":"e_1_2_8_21_2","first-page":"685","volume":"62","author":"Taran L. D.","year":"1997","journal-title":"Biochemistry (Mosc.)"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi001074q"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi0255367"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2006.05.012"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M203033200"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01828.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-008-9774-6"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.130"},{"key":"e_1_2_8_29_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood.V88.7.2603.bloodjournal8872603","volume":"88","author":"Brinkhous K. M.","year":"1996","journal-title":"Blood"}],"container-title":["Biotechnology and Applied Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbab.32","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bab.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T04:52:38Z","timestamp":1696999958000},"score":1,"resource":{"primary":{"URL":"https:\/\/iubmb.onlinelibrary.wiley.com\/doi\/10.1002\/bab.32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1002\/bab.32"],"URL":"https:\/\/doi.org\/10.1002\/bab.32","archive":["Portico"],"relation":{},"ISSN":["0885-4513","1470-8744"],"issn-type":[{"value":"0885-4513","type":"print"},{"value":"1470-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}